30.4 C
Vientiane
Sunday, May 18, 2025
spot_img
Home Blog Page 1013

Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine

Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infection


HONG KONG SAR – Media OutReach Newswire – 12 November 2024 – Immuno Cure BioTech (“Immuno Cure“), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce the completion of a first-in-human novel therapeutic HIV vaccine, ICVAX, Phase I clinical trial with encouraging findings of exceptional safety and promising immunogenicity profiles. This represents a significant step of ICVAX towards achieving antiretroviral therapy (“ART“) free virological control by ICVAX and ultimately accomplishing as a functional cure of HIV/AIDS.

ICVAX is the result of the collaboration between Immuno Cure and Hong Kong AIDS Foundation, HKU AIDS Institute, Hong Kong Science & Technology Parks Corporation and the Shenzhen Third People’s Hospital.
ICVAX is the result of the collaboration between Immuno Cure and Hong Kong AIDS Foundation, HKU AIDS Institute, Hong Kong Science & Technology Parks Corporation and the Shenzhen Third People’s Hospital.

Globally, there are more than 39 million people living with HIV (“PLWH“) and over 40 million deaths since HIV was discovered in 1981. The currently available ART, while highly efficacious, does not cure HIV/AIDS, highlighting the need for an effective immunotherapy to assist ART. Such immunotherapy can potentiate host immune response, aiming to achieve a state of ART-free virological control, and ultimately a complete suppression of virus to an undetectable level in blood for a prolonged period of time, and hence achieving functional cure. Immuno Cure’s ICVAX aims to induce broadly reactive polyfunctional viral-specific T cells to achieve sustained HIV-1 virological control in the absence of ART.

This Phase I clinical trial is a randomized, double-blinded, placebo-controlled, dose-escalation study, approved by the National Medical Products Administration (“NMPA“) and carried out at The Shenzhen Third People’s Hospital (“Shenzhen Third Hospital“), for the evaluation of the safety, maximal tolerating doses, and for the exploration of immunogenicity of ICVAX in clinically stable HIV-1-infected patients whose virus replication are well-suppressed by antiretroviral therapy (clinicaltrials.gov no. NCT06253533), (“Phase I Trial“). A total of 45 participants were recruited and randomly assigned into three dosing groups (1 mg, 2 mg, and 4 mg groups), with an ICVAX-to-placebo ratio of 12:3 in each cohort. ICVAX was delivered by electroporation using Immuno Cure’s NMPA-approved Class II Teresa EP device (“Teresa EP“).

All trial data were reviewed by the Data Safety Monitoring Board (“DSMB”) and unblinded in late September 2024. ICVAX was well tolerated and had a favorable safety profile at all doses studied. All 45 participants completed the scheduled visits. All reported treatment-related adverse events were mild, and no treatment-related severe adverse events were reported. Overall, ICVAX vaccine recipients demonstrated promising T cell responses. In those receiving the optimal ICVAX dose, a large majority had more than 2-fold increase in T cell responses. Critically, ICVAX could enhance functional T cells previously found in Elite Controllers (“EC“) for HIV-1 control. The primary and secondary endpoints of the Phase I trial have been met. Immuno Cure plans to share such promising findings from the Phase I Trial in scientific conferences and in a peer-reviewed scientific journal. The Phase I Trial data will be submitted to regulatory agencies for review for advancing the vaccine into a Phase II efficacy clinical trial.

Dr. Hongzhou LU MD, PhD, President of Shenzhen Third Hospital and Co-Principal Investigator of the Phase I Trial, said “We are incredibly excited with these unprecedented results of the Phase I clinical trial of ICVAX upon unblinding after thorough review and clearance by the DSMB. These promising trial data laid a solid foundation for the upcoming Phase II clinical trial, and for ICVAX to ultimately achieve ART-free virological control in HIV-1 patients and potentially the long-awaited functional cure of HIV/AIDS for PLWH. We thank the volunteers for their selfless participation and commitment to finish the entire trial. I believe many patients are eager to join the next stage of clinical trials of the candidate HIV vaccine.”

HKU AIDS Institute has been leading a collaborative research initiative in association with Immuno Cure and other academic institutions on ICVAX, which was awarded significant grant funding twice under the Theme-based Research Scheme (“TRS“) from the Research Grants Council (“RGC“), aggregating to some HK$ 113.8 million. In the first 5-year term of TRS 18/19 (8th round), HK$47.1 million was granted for basic research of ICVAX, studying PD-1-Enhanced DNA vaccine-based combination immunotherapy in monkey models and human subjects. Recently, in the second 5-year term of TRS 24/25 (14th round), HK$66.7 million was granted for carrying out of further translational research, including multicenter clinical trials in the coming five years. The collaborative research was also granted an aggregate amount of HK$ 5.99 million by the Innovation and Technology Commission (“ITC“) for early-stage pre-clinical studies under the University and Industry Collaboration Program (“UICP“).

Prof. Zhiwei CHEN PhD, Founding Director of HKU AIDS Institute, Tenured Professor and Chair of Immunology and Immunotherapy in the Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong (HKU), and Suen Chi-Sun Professor in Clinical Science, inventor of the patented PD-1 Enhanced DNA vaccine technology and the Principal Scientific Advisor of Immuno Cure, said “The Phase I Trial preliminary data demonstrated satisfying safety and immunogenicity profiles of ICVAX in PLWH. It is encouraging to discover that ICVAX enhances functional T cells previously found in EC for HIV-1 suppression. Our team members are very grateful for the significant amount of funding from RGC and ITC, which have enabled us to accomplish our interim achievements at this stage and to further expand our translational research, including an upcoming Phase II clinical trial for the benefit of more and more PLWH.”

Immuno Cure was granted a maximum amount of ΗΚ$8 million funding for this Phase I Trial under the Clinical Translational Catalyst (“CTC“) programme of the Institute for Translational Research (“ITR“) of the Hong Kong Science and Technology Parks Corporation (“HKSTP“). The CTC program is a highly specialized platform to provide all-round support to biomedical companies in the pre-clinical and early clinical stages, aiming to transform Hong Kong and the Greater Bay Area to become the go-to destination for translational medicine in the region. Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, life-changing therapies and technologies to patients.

Ms. Gracie Ng, Chief of Staff and Acting Chief Corporate Development Officer, HKSTP said, “The HKSTP team was thrilled to hear the news that Immuno Cure has completed Phase 1 clinical trial for ICVAX. This pioneering vaccine represents a major advancement in our fight against HIV/AIDS. The success highlights our role as one of the global leaders in translational development, producing innovative therapies to improve patients’ quality of life.”

The Hong Kong AIDS Foundation, established in 1991, is a non-governmental social service organization with a mission to limit the spread of HIV infection in the community. Throughout the years, the Foundation has been actively engaged in the promotion of AIDS education, the provision of services, and the nurturing of a harmonious and caring environment for those infected with or affected by HIV/AIDS.

Dr. Che Hung LEONG MD, PhD, GBM, GBS, JP, President of Hong Kong AIDS Foundation and the Chairman of the Advisory Board of Immuno Cure said: “It is exciting to see the positive results of ICVAX, Immuno Cure’s therapeutic HIV vaccine, from its Phase I clinical trial. The trial data shows that ICVAX might potentially provide an alternative to ART which would alleviate the burden of drug compliance of patients. These results suggest that we may be on the brink of a breakthrough with a therapy that could enhance the quality of life for many PLWH and provide them a hope for functional cure in the longer term.”

Immuno Cure is communicating with the NMPA for the upcoming multi-centre, double-blinded, placebo-controlled, dose-finding Phase II clinical trial. The trial will aim to evaluate the immunogenicity and efficacy in controlling HIV viral load. It is anticipated to commence in mid-2025.

Dr. Xia JIN MD PhD, CEO of Immuno Cure concludes, “The encouraging outcomes of the Phase I Trial are attributed by fruitful collaboration for over 8 years between Immuno Cure and Prof. Chen of HKU-AIDS Institute, representing a significant milestone of the development of ICVAX. Looking ahead, we shall move on with our BLA application under NMPA’s breakthrough drug regulatory regime after meeting the expected end points of the Phase II clinical trial. The success of development of ICVAX will not only prove the novelty of our DNA vaccine technology platform, but also mark a giant step towards functional cure of HIV/AIDS, and to enable the relief of burden on PLWH and improvement of their quality of life. Lastly, we thank the volunteers for their participation and the doctors and nurses at the Shenzhen Third Hospital trial site, as well as other clinical trial collaborators, CRO, SMO, CMO and clinical laboratories, for their dedication and diligence, for they are the key elements of the smooth completion of this trial. Also, we would like to thank HKSTP, ITC, and RGC for their generous funding support. Next, we plan to launch a cross-border multi-centre Phase II clinical trial in mid-2025, including CUHK Phase 1 Clinical Trial Centre, Shenzhen Third People’s Hospital, Guangzhou Eighth People’s Hospital, etc. Through this trial, we look forward to cooperating with the Greater Bay Area International Clinical Trial Institute (“GBAICTI“), which will soon begin its service to promote advanced biomedical technology research, clinical trials, and applications in Hong Kong and the Greater Bay Area, aiming to jointly develop Hong Kong into an international medical innovation hub.”

Hashtag: #ImmunoCure #醫克生物 #医克生物

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher education in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled “Potentiating Host Immunity for HIV-1 Functional Cure”, the institute is currently leading the second 5-year term research entitled “Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions”.

To learn more about HKU and AIDS Institute of HKU, please visit and

About The Shenzhen Third People’s Hospital

The Shenzhen Third People’s Hospital / The Second Affiliated Hospital of Southern University of Science and Technology was founded in 1985 by the Shenzhen municipal government. It is a grade A tertiary research-oriented hospital characterized by strong specialty and comprehensive medical services. The hospital covers an area of around 198,400 square meters with 223,000 square meters construction area and 2416 hospital beds, including 1008 in negative pressure wards in the emergency campus for infectious diseases. By far, the hospital has become a large, well-equipped clinical and research center of infectious diseases in the Guangdong-Hong Kong-Macau Greater Bay Area offering comprehensive services. Thus, it contributes to the control of infectious disease and major public health emergency and benefits patients in Shenzhen and adjacent areas.

To learn more about Shenzhen Third People’s Hospital, please visit

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,000 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at .

About Hong Kong AIDS Foundation Limited

The Hong Kong AIDS Foundation was established in 1991 and is a non-governmental social service organisation. The Foundation’s mission is to limit the spread of HIV infection in the community. Throughout the years, the Foundation has been actively engaged in the promotion of AIDS education, the provision of services, and the nurturing of a harmonious and caring environment for those infected with or affected by HIV/AIDS.

To learn more about Hong Kong AIDS Foundation, please visit .

CamScanner takes ESG to the next level ahead of 2025 with sustainable education and community support

Company’s innovative digital tools demonstrate its commitment to saving paper, supporting higher-education and strengthening communities


NEW YORK, US – Media OutReach Newswire – 12 November 2024 – CamScanner, a global leader in document-scanning apps with over 300 million users, ramped up its ESG initiatives ahead of 2025 to focus on global sustainability and supporting higher-education through the company’s innovative management tools for digital documents.

CamScanner takes ESG to the next level ahead of 2025 with sustainable education and community support

Earlier this year, CamScanner launched the Campus Empowerment Program, a first-of-its-kind initiative aimed at supporting university students and faculty in enhancing their academic lives. This program builds on CamScanner’s longstanding commitment to education, which has already benefited nearly 150,000 university students and thousands of schools across more than 100 countries over the past several years. By making education more accessible, CamScanner ensured that students had the tools necessary to thrive in their studies.

In addition to its work in education, CamScanner promoted social responsibility this year by tackling the technology gap in remote areas. In rural South Sulawesi, Indonesia, where villages often have only one print shop that’s relatively expensive, a local resident uses CamScanner to help her neighbors scan and upload their personal documents from the comfort of their homes. Villagers lauded CamScanner for its ability to produce clean, clear scans with just the tap of a button. This reduces the need to seek out print shops or travel several kilometers to government offices, making it possible for many people who previously lacked the means to apply for social security benefits.

CamScanner’s dedication to being environmentally sustainable also enhanced its impact on education and supporting communities. The company’s #LightsOffScreensOff campaign for Earth Hour 2024 encouraged users to turn off non-essential electronics and reduce paper waste. In 2023 alone, CamScanner’s digital impact contributed to preventing 250,000 tons of carbon emissions, equal to planting about 10 million trees.

“CamScanner has long championed ESG, and we will continue to dedicate ourselves to ESG in the future,” said Kevin Cao General Manager of CamScanner. “We believe sustainable practices and social responsibility are essential for driving positive change and empowering individuals to thrive. 2024 was a fantastic example of that, and 2025 will be even better.”

Follow CamScanner on X, YouTube, and Instagram for our latest updates and campaigns.

Hashtag: #CamScanner

The issuer is solely responsible for the content of this announcement.

Arrow Electronics Brings Engineering and Supply Chain Capabilities for a Broader Ecosystem across GBA


SHENZHEN, CHINA – Media OutReach Newswire – 12 November 2024 – With the theme of “Shaping a smarter and greener tomorrow,” global technology solutions provider Arrow Electronics organized its annual Arrow Technology Showcase event today in Shenzhen, a sci-tech and advanced manufacturing hub in China’s Greater Bay Area (GBA) region.

Arrow Electronics Brings Engineering and Supply Chain Capabilities for a Broader Ecosystem across GBA
Arrow Electronics Brings Engineering and Supply Chain Capabilities for a Broader Ecosystem across GBA

The event featured over 100 innovative products and solutions tailored for edge AI, e-mobility, green energy, and smart industrial and manufacturing applications across various market sectors. The event drew hundreds of technology companies, manufacturers, solution providers, and tech startups from the GBA region.

Industry data forecasts that the Asia-Pacific industrial IoT market to reach US$135 billion by 2030[1]. To support tech companies and startups in accelerating their idea-to-product commercialization journey, Arrow has collaborated with several tech startup incubators in the GBA. These include XbotPark, a global startup incubator focused on robotics and smart hardware, and the Hong Kong Center for Construction Robotics (HKCRC), a scientific research and entrepreneurship platform committed to bringing robotics, automation, and AI technologies into the construction industry to promote its advancement.

Led by Haozhen Li, a project lead at HKCRC, the rebar-tying robot was one of the intelligent construction technology products showcased. This robot, equipped with advanced AI and sensing technologies, can automatically identify and tie rebar nodes, switch tracks, and avoid obstacles. Its enhanced capability to tie nodes in just five seconds with 99.6% accuracy significantly helps improve worker safety, especially for those handling hazardous tasks. The compact design also makes it easy to transport and install in various settings, including infrastructure construction, prefabricated factories, and more.

“I’m thrilled to be involved in the research and development of high-tech projects that utilize robotics and automation technologies. These innovations are driving the transformation of the traditional construction industry from labor-intensive to technology-driven. Thanks to global technology companies like Arrow, aspiring researchers are given entrepreneurial opportunities and support to become entrepreneurs,” said Haozhen Li.

Two other noteworthy innovative products showcased include an IoT-enabled smart flatness meter that digitally assesses the flatness, levelness, and verticality of construction sites, and a handheld LiDAR scanner created by Skyland Innovation, a tech startup committed to merging cutting-edge robotics with advanced 3D reconstruction technologies.

“As we enhance our robotic product offerings and scale up our business, we are excited to be able to access Arrow’s advanced electronic components, design engineering resources, and go-to-market support. With the support of HKCRC and global technology companies like Arrow, we can leverage ecosystem resources to reach a broader market and maximize our growth potential with our advanced robotics and 3D reconstruction technology solutions,” said Jie Pan, CEO of Skyland Innovation.

Autonomous and intelligent devices are transforming the smart manufacturing industry by enhancing efficiency, productivity, and safety. These devices, showcased at the event, feature smart power management, advanced motor control, and AI-imaging technologies, allowing them to perform complex tasks with minimal human intervention. Additionally, AI-powered systems are employed for predictive maintenance, quality control, and real-time data analysis, enabling manufacturers to make informed decisions and improve overall operational efficiency.

The event also highlighted various mobility and electrification solutions, including battery management systems , matrix headlamps, interior lighting, automotive MCU boards, gateways and clusters, ultra-wideband, telematics boxes, traction inverters, and onboard chargers.

“The proliferation of AI-powered technology, increasing industrial automation and digitization, the electrification of everything, and the demand for energy-efficient and miniature devices are driving the demand for semiconductors as well as interconnect, passive, and electromechanical components,” said Jacqueline Leung, Arrow’s president for its Greater China components business. “We recognize that engineering resources and capabilities are essential for startups and innovators to maximize their business potential. We are committed to continuing our collaboration with tech incubation communities such as XbotPark and HKCRC to empower innovators and entrepreneurs to overcome technological and supply chain challenges and bring their impactful and innovative ideas to market faster.”

To learn more about robotics and smart industrial solutions, click here for more information.

[1] https://www.meticulousresearch.com/pressrelease/858/asia-pacific-industrial-iot-market-2030

Hashtag: #ArrowElectronics




Wechat: arrow-cn

The issuer is solely responsible for the content of this announcement.

About Arrow Electronics

Arrow Electronics (NYSE:ARW) sources and engineers technology solutions for thousands of leading manufacturers and service providers. With global 2023 sales of $33 billion, Arrow’s portfolio enables technology across major industries and markets. Learn more at arrow.com.

Kwoon Chung Bus x YAS – Groundbreaking Cross-Border Embedded Insurance for a Seamless Travel Experience Between Hong Kong and Mainland China


HONG KONG SAR – Media OutReach Newswire – 12 November 2024 – Kwoon Chung Bus has partnered with YAS, an InsurTech pioneer, to launch Hong Kong’s first embedded travel insurance specifically designed for cross-border bus trips. This partnership introduces a seamless, embedded travel insurance for the millions of passengers who cross the Hong Kong-Mainland China border each year. With this new integration, YAS and Kwoon Chung are transforming cross-border travel with enhanced safety and peace of mind.

Kwoon Chung Bus has partnered with YAS, an InsurTech pioneer, to launch Hong Kong's first embedded travel insurance specifically designed for cross-border bus trips. (From right) Mr. William Lee, Co-founder of YAS, Mr. Adrian Leung, Director of ZAKC Limited, Mr. Andy Ann, Co-founder of YAS, and Mr. Timothy Wong, COO of Kwoon Chung Group
Kwoon Chung Bus has partnered with YAS, an InsurTech pioneer, to launch Hong Kong’s first embedded travel insurance specifically designed for cross-border bus trips. (From right) Mr. William Lee, Co-founder of YAS, Mr. Adrian Leung, Director of ZAKC Limited, Mr. Andy Ann, Co-founder of YAS, and Mr. Timothy Wong, COO of Kwoon Chung Group

In collaboration with renowned retailers and ecosystem partners, YAS goes beyond insurance to offer travellers an enhanced overall travel experience with a range of shopping discounts, fostering cross-border tourism and supporting Hong Kong and Greater Bay Area development.

Embedded Insurance for Peace of Mind

Kwoon Chung Bus customers who purchase memberships or points via the “Hong Kong-Mainland Express” WeChat Mini Program will receive complimentary embedded travel protection from YAS for their initial journey. YAS Co-Founder, Mr. William Lee, stated, “At YAS, our mission is to provide the fastest, simplest embedded insurance experience, empowering fellow citizens to start their journeys with peace of mind. This collaboration with Kwoon Chung marks just the beginning of a new era in cross-border travel, and we are dedicated to driving further innovation to crown Hong Kong as the global insurance pioneer, making insurance smarter, more accessible, and more convenient”. YAS is proud to partner with Generali Hong Kong once again to deliver this industry-leading insurance program.

Collaborating with Retail Partners for an Unmatched Shopping Experience

To elevate the travel experience, YAS x Kwoon Chung is introducing the “Double Delight” benefits for members. In partnership with notable retailers, including Maxim’s, Kee Wah Bakery, Catalo, Hang Lung Properties, and the hello Hang Lung Malls Rewards Program, members of the Kwoon Chung bus enjoy shopping discounts at over 50 outlets across Hong Kong Island, Kowloon, and the New Territories. Travellers can disembark at various locations to explore the vibrant city and enjoy an exciting shopping experience.

Driving Tourism Growth in the Greater Bay Area with Future Prospects

This collaboration represents an innovative first in cross-border bus service, both Kwoon Chung Bus and YAS look forward to future partnerships to drive tourism development in the Greater Bay Area. Mr. Timothy Wong, COO of Kwoon Chung Group, expressed his enthusiasm, stating, “YAS’s embedded travel insurance not only offers travellers valuable protection but enhances their safety and convenience. We look forward to supporting Greater Bay Area tourism, creating a superior travel experience for all”.

Insurance Coverage Overview:

Accidental Medical Expenses

  • Adults (18-79): Up to HK$5,000
  • Children (Under 18) and Seniors (80+): Up to HK$2,500
  • Therapy, Acupuncture & Dental (Medically Necessary): HK$200/day
  • Deductible: HK$500 per incident

Personal Belongings

  • Documents & Baggage (e.g., phones, laptops, tablets, cameras): Up to HK$10,000
  • Limit per Item: HK$1,000
  • Deductible: HK$500 per incident

Accidental Death or Permanent Disability

  • Adults (18-79): Up to HK$200,000
  • Children (Under 18) and Seniors (80+): Up to HK$100,000

Terms and conditions apply. Learn more: https://membership.yas.io/zh/kc/campaign_gbt/
Hashtag: #KwoonChungBus #YAS

The issuer is solely responsible for the content of this announcement.

About YAS

YAS is an award winning InsurTech company in Asia, leveraging cutting-edge AI and blockchain technology to deliver dynamic, on-demand insurance solutions. YAS (IA License Number FA2648) is a registered insurance agency in Hong Kong, distributing general insurance products under the Insurance Companies Ordinance (Chapter 41 of the Laws of Hong Kong). For more information, visit .

About Kwoon Chung Bus

Founded in 1948 by the late Mr. Kwoon Chung Wong, Kwoon Chung Bus Holdings Limited has grown to become the largest non-franchised bus and luxury coach operator in Hong Kong. The group was listed on the Main Board of the Hong Kong Stock Exchange in 1996 and currently operates approximately 1,285 non-franchised public buses and 428 luxury coaches as of March 31, 2024.

About Assicurazioni Generali S.p.A

In 1981, Assicurazioni Generali S.p.A was first registered as an authorised insurer in Hong Kong, with the business extending into the life insurance sector in 2016 with Generali Life (Hong Kong) Limited. With a combination of local knowledge and Generali Group’s global expertise, we develop unique and innovative life insurance, general insurance, speciality insurance, and employee benefits solutions to meet the needs of our customers.

About ZAKC Limited

ZAKC Limited is a joint venture company established by Kwun Chung Bus and Zhong An, committed to providing customers with an online service platform for Guangdong-Hong Kong-Macao cross-border transportation, established in 2019 and located in Hong Kong S.A.R..

Double Delight Membership Offer

From November 8 to December 8, Hong Kong-Mainland Express members can purchase the Double Delight offer for a special promotion half-price at $19, receiving first-trip travel insurance and retail discounts.

Insurance coverage is underwritten by Generali Hong Kong and arranged by YAS Digital Limited (“YAS”) (IA License Number FA2648). Kwoon Chung Bus is not an intermediary or insurance agent of Generali or any other licensed insurance company.

Vietnam Pavilion: A Gateway to International Business Opportunities for European Enterprises


HANOI, VIETNAM – Media OutReach Newswire – 12 November 2024 – The European – Vietnam Free Trade Agreement (EVFTA), which was officially signed in 2019, has marked a significant milestone in strengthening economic cooperation between the two regions. To facilitate international businesses, particularly European enterprises in accessing products information, finding business partners and expanding into the Vietnamese market, the Vietnam Trade Promotion Agency under the Ministry of Industry and Trade of the Socialist Republic of Vietnam is proud to introduce the Vietnam Pavilion on Alibaba.com e-commerce platform.

Vietnam Pavilion: A Gateway to International Business Opportunities for European Enterprises

For more information and to explore the Vietnam Pavilion, please visit: https://sale.alibaba.com/p/vietnampavilion-vnfeaturedbusiness/index.html

The Vietnam Pavilion is not only a showcase for high-quality, reputable products bearing the “Made in Vietnam” label but also a gateway for international businesses to explore cooperation opportunities with Vietnamese enterprises. With a diverse product range encompassing agricultural products, food, handicrafts, furniture, pharmaceuticals and more, the Vietnam Pavilion is an attractive destination for European businesses seeking opportunities to expand their operations in Vietnam and Southeast Asia region.

Through the Vietnam Pavilion, European businesses will benefit from:

Access to products at competitive prices: Thanks to the EVFTA, tariffs on 90 per cent of goods exported from Vietnam to Europe have been reduced or eliminated. This significant reduction in trade barriers makes Vietnamese products much more affordable, giving European businesses a price advantage compared to sourcing from other regions. Products from Vietnam, ranging from textiles to agricultural goods, now come at highly competitive prices.

Quality-assured products: Businesses exhibiting at the Vietnam Pavilion are carefully selected by the Vietnam Trade Promotion Agency and Alibaba.com e-commerce platform. This ensures that only companies meeting strict standards are included. Products offered have transparent origins and come with internationally accredited certifications. Therefore, buyers can be confident in the origin of the goods.

Trade opportunities with Southeast Asia enterprises: By connecting with Vietnamese companies through the Vietnam Pavilion, European businesses open doors to broader opportunities in Southeast Asia – a dynamic economic development region. Vietnam is strategically located within the ASEAN region, and many suppliers have strong regional networks. This enables European businesses tapping into a growing, interconnected market with competitive pricing and diverse product offerings. Enterprises from Europe therefore can enhance their supply chain flexibility and market reach.

It can be said that the Vietnam Pavilion on Alibaba.com e-commerce platform serves as a gateway for European businesses to access high-quality Vietnamese products at competitive prices and opens up a new trade channel in Southeast Asia.

With support from the Vietnam Trade Promotion Agency and Alibaba.com e-commerce platform, the Vietnam Pavilion will serve as an ideal platform for European businesses to grow their operations, strengthen their gobal supply chains and expand into international markets.

For more detailed information and support, please visit:

https://sale.alibaba.com/p/vietnampavilion-vnfeaturedbusiness/index.html

We look forward to collaborating with European businesses through the Vietnam Pavilion project on the Alibaba.com e-commerce platform.

Vietnam Trade Promotion Agency – Ministry of Industry and Trade of the Socialist Republic of Vietnam

Address: 20 Ly Thuong Kiet Street, Hoan Kiem District, Hanoi, Vietnam

Website: https://vietrade.gov.vn/

The issuer is solely responsible for the content of this announcement.

Laos to Enforce Ban on Unregistered, Unlabeled Food Products in 2025

Laos to Enforce Ban on Unregistered, Unlabeled Food Products in 2025
Importers, wholesalers, and local manufacturers must ensure that all products are registered with the Department of Food and Drug and labeled in Lao by 31 December. (photo credit: Lao PDR Trade Portal)

The Lao Ministry of Industry and Commerce has announced new regulations, requiring all food products to carry proper registration, Food and Drug Department (FDD) numbers, and Lao-language labeling, to ensure consumer safety, to be in effect from 1 January 2025.

VinFast secures top market position in Vietnam


HANOI, VIETNAM – Media OutReach Newswire – 12 November 2024 – VinFast announced it has delivered more than 11,000 electric vehicles (EVs) to domestic customers in October, bringing its total sales since the beginning of the year to over 51,000 EVs. This positions VinFast as the best-selling automotive brand in the Vietnamese market for October and the first ten months of 2024. VinFast is confident in maintaining its domestic leadership and contributing to the green transition of Vietnam’s transportation sector.

Since the beginning of the year, VinFast has delivered over 51,000 EVs in the Vietnamese market, officially becoming the best-selling automotive brand in the country.
Since the beginning of the year, VinFast has delivered over 51,000 EVs in the Vietnamese market, officially becoming the best-selling automotive brand in the country.

Following strong sales in September 2024, VinFast continued its momentum in October by delivering more than 11,000 EVs—a 21% increase over the previous month. The VF 3 and VF 5 were the top-selling models, with nearly 5,000 EVs and over 2,600 EVs sold, respectively.

Since the beginning of the year, VinFast has delivered over 51,000 EVs in the Vietnamese market. With a substantial number of pre-orders, large-scale production capacity, as well as a continuously expanding network of dealership and charging stations nationwide, VinFast is confident in maintaining its top position in the Vietnamese market and further widening its lead over competitors.

VinFast becoming the best-selling car brand in its domestic market marks a significant breakthrough for Vietnam automotive industry. In just over five years since market entry, VinFast managed to not only establish a firm foothold but also overtake foreign competitors to secure the largest market share. Notably, VinFast is also the first electric vehicle brand to surpass gasoline-powered competitor to become the market-leading brand, just two years after its transition to a pure-play brand.

VinFast’s remarkable growth is a testament to the capabilities and resilience of the Vietnamese people in high-tech industry, and underscores strong consumer support for eco-friendly, smart electric vehicles. Vietnam is now among the few countries where domestic auto sales are led by a pure-play EV company.

VinFast secures top market position in Vietnam

Reflecting on this historic milestone, Mr. Pham Nhat Vuong, Chairman of Vingroup and CEO of VinFast Global, shared: “Achieving this milestone is, first and foremost, thanks to the support of hundreds of thousands of VinFast customers—those who have pioneeringly backed a young Vietnamese brand, who have shown patience in using our products, and have provided invaluable feedback to improve VinFast’s products and services from the start. Their insights and support have helped VinFast make improvements in product and service quality to reach where we are today. On behalf of all employees at Vingroup and VinFast, I extend my deepest gratitude to every VinFast customer and pledge that we will not rest on our current achievements. We will continually strive to research and implement solutions to elevate our product and service quality to increase customer satisfaction even further. I’d also like to thank the entire VinFast and Vingroup team for their resilience in overcoming numerous challenges and doubts. Together, we have wholeheartedly and creatively fulfilled our mission.

Currently, VinFast offers seven electric vehicle models across all segments in the Vietnamese market, from mini-SUVs to E-SUVs, with competitive pricing options that cater to diverse customer needs and remain attractive compared to gasoline vehicles in the same segment. VinFast is also actively expanding internationally, strengthening its presence in multiple countries and regions worldwide to contribute to the global shift toward electric mobility.

The Company also announced that it will release its 3Q24 financial results before the market opens on November 26, 2024. On the same day, VinFast’s management will hold a live webcast to discuss the Company’s business performance and strategy. Details for the call are below:

What: VinFast Q3 2024 Financial Results and Q&A Webcast
When: Tuesday, November 26, 2024
Time: 8:00 a.m. Eastern Standard Time
Live webcast: https://edge.media-server.com/mmc/p/5725mupo

A replay of the webcast will also be made available on the Company’s website.

For additional information, please visit ir.vinfastauto.us.

Investor Relations Email: ir@vinfastauto.com
Hashtag: #VinFast #EVs #VF3 #VF5 #topmarket

The issuer is solely responsible for the content of this announcement.

About VinFast

VinFast (NASDAQ: VFS), a subsidiary of Vingroup JSC, one of Vietnam’s largest conglomerates, is a pure-play EV manufacturer with the mission of making EVs accessible to everyone. VinFast’s product lineup today includes a wide range of electric SUVs, e-scooters, and e-buses. VinFast is currently embarking on its next growth phase through rapid expansion of its distribution and dealership network globally and increasing its manufacturing capacities with a focus on key markets across North America, EMEA and Asia. Learn more at:

CCM Costume Rental Launches Newly Revamped Website To Streamline Customer Experience

SINGAPORE – Media OutReach Newswire – 12 November 2024 – CCM Costume Rental, Singapore’s premier costume rental service, is excited to announce the launch of its newly revamped website, designed to provide customers with a seamless, user-friendly experience when searching for costumes for any event. Featuring an expanded online catalogue, customers can now find the perfect costume with ease, whether it’s for a corporate function, themed party, or a quick social media post.

With thousands of costumes available, the updated platform is designed to meet the needs of both individual and corporate clients, responding to the increased demand for convenient, high-quality costume rentals. The new site offers a streamlined browsing experience and an intuitive interface, allowing customers to quickly browse, select, and order costumes from the comfort of their homes or offices.

Enhanced user experience and upgraded features to meet growing customer demand
“We’re thrilled to unveil our new website, which reflects our commitment to enhancing customer satisfaction and expanding our service capabilities,” said Hasyna Neo, Head of Rental of CCM Costume Rental. “Our upgraded platform is part of our ongoing effort to make costume rental a hassle-free, enjoyable experience for everyone.”

Whether customers need costumes for a themed dinner, a special event, or the latest TikTok trend, CCM Costume Rental provides a diverse selection to suit any occasion. The website also showcases the company’s unique Costume on the Move service, which brings costumes directly to offices for convenient fittings and tailored sizing, complete with free delivery and supported by in-house seamstresses to ensure a perfect fit every time.

For more information and to explore the upgraded catalogue, visit https://ccm.com.sg/ today.

Hashtag: #CCM

The issuer is solely responsible for the content of this announcement.

CCM Costume Rental

CCM Costume Rental is Singapore’s premier costume rental service, offering an extensive collection of meticulously maintained costumes for any themed event, from corporate functions to private parties. With our unique Costume on the Move service and in-house seamstress team, we provide convenient fittings and tailored sizing solutions to ensure a perfect fit. At CCM Costume Rental, we pride ourselves on delivering not only high-quality costumes but also exceptional customer service. Visit us today and experience the magic of dressing up!